Hematologic malignancies: an opportunity for targeted drug therapy.
Gabrilove
J L
JL
The Derald H. Ruttenberg Cancer Center, Mount Sinai School of Medicine, New York, New York 10029, USA. janice.gabrilove@mssm.edu
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D001374:Azacitidine / Q000627:therapeutic use; D004273:DNA, Neoplasm / Q000187:drug effects; D004921:Erythropoietin / Q000627:therapeutic use; D019337:Hematologic Neoplasms / Q000188:drug therapy*; D006801:Humans; D011994:Recombinant Proteins; D013921:Thrombocytopenia / Q000139:chemically induced
D020533:Angiogenesis Inhibitors; D000964:Antimetabolites, Antineoplastic; D004273:DNA, Neoplasm; D011994:Recombinant Proteins; D004921:Erythropoietin; D001374:Azacitidine